U.S. & Europe Extractable And Leachable Testing Services Market Size, Share & Trends Analysis Report By Application (OINDP, Parenteral Drug Products), By Product (Single-use, Drug Delivery Systems), And Segment - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. & Europe extractable and leachable testing services market size was estimated at USD 619.60 million in 2022 and is expected to surpass around USD 2,552.78 million by 2032 and poised to grow at a compound annual growth rate (CAGR) of 15.21% during the forecast period 2023 to 2032.

Key Takeaways:

• The U.S. held the largest market share of 57.19% in 2022.
• Europe is expected to witness a significant CAGR of 14.87% from 2023 to 2032.
• On the basis of products, the container closure systems segment held the largest revenue share of 31.6% in 2022.
• Thus, increasing demand for container closure systems in the market is anticipated to drive the segment growth over the forecast period.
• The orally inhaled and nasal drug products segment was the largest in 2022 andaccounted for the largest revenue share of 42.16%.
• Thus, increasing the demand for extractable and leachable testing services over the forecast period.
• The parenteral drug products segment is projected to witness the fastest CAGR of 17.33% over the forecast period.

U.S. & Europe Extractable And Leachable Testing Services Market Report Scope

Increasing regulatory scrutiny on the quality of healthcare products and rising emphasis on product safety are key drivers fueling market growth. Moreover, flourishing pharmaceutical and biotechnology sectors across the U.S. & Europe and supportive government legislation are further projected to support market expansion. The COVID-19 pandemic positively impacted market growth owing to the high demand for novel therapeutics and healthcare products.

The pandemic created a higher demand for pharmaceuticals, comprising treatments, vaccines, and medical devices. As companies scaled up manufacturing these products, the demand for extractable and leachable testing services increased to ensure product safety and compliance with regulatory requirements. In addition, with the introduction of new drugs and medical devices during the pandemic, regulatory bodies increased their emphasis on product safety and quality. As a result, companies had to perform exhaustive leachable testing as a part of their new product development process. Extractable and leachable testing is the analysis of harmful foreign materials that could enter a patient’s body with devices or medicines.

Various pharmaceutical and biotechnology companies use different extractable testing services to safeguard their products from regulatory scrutiny. The regulatory framework for extractable and leachable testing has become more stringent as it is directly concerned with patient safety. In March 2022, the UK government with its Medicines and Healthcare Products Regulatory Agency announced a change in the UK clinical trial regulations. Thereby increasing the demand for extractable and leachable testing services over the forecast period. In addition, rising government support and increasing investment opportunities in the biopharmaceutical domain are anticipated to boost industry growth & positively affect the market.

For instance, in April 2021, venture capital firms invested over USD 36.6 billion in biopharmaceutical companies in the U.S., the UK, and countries in the European Union, accounting for an increase of around 281% from 2017. Thereby increasing the market demand over the forecast period. Furthermore, the growing demand for innovations in bioprocess engineering has led to considerable developments in single-use systems. Advancements in this domain are also fueled by the high usage rate of biopharmaceuticals in recent times.

Furthermore, the increasing number of studies conducted to evaluate the efficiency of single-use bioprocesses is also aiding the rise in awareness about these technologies. Single-use technologies also offer a wide range of benefits, such as a lower risk of cross-contamination, shorter turnaround times, cost-effectiveness, and higher flexibility for altering production volumes. Thus, the rising adoption of single-use technology raised several issues regarding leachable and extractable, as single-use systems can easily come in contact with products and affect their safety and quality. Thus, augmenting the demand for extractable and leachable testing services.

Product Insights

On the basis of products, the container closure systems segment held the largest revenue share of 31.6% in 2022. The rising use of container closure systems in formulations because of their ability to provide long-term stability is boosting the revenue share of this segment. The container closure systems also consist of several package/delivery systems and can leach over time, making E & L testing extremely essential for CCS. Adequate container closure systems are important to maintain the drugs' safety, sterility, and quality. Various cases have been observed involving the loss of safety or formation of harmful contaminants due to the transfer of impurities from container closure systems to pharmaceutical products. For instance, Apotex Corp. recalled the Brimonidine Tartrate Ophthalmic Solution, 0.15%, in March 2023.

Thus, increasing demand for container closure systems in the market is anticipated to drive the segment growth over the forecast period. The single-use systems segment is expected to grow at a significant growth rate of 16.91% from 2023 to 2032. Single-use components and systems usage has increased significantly in commercial & clinical biopharmaceutical manufacturing. These components are generally made up of polymers or plastics. The single-use systems & components provide several advantages, such as speed, flexibility, and operation efficiency, over reusable components. However, the major concern with these SUS is that compounds can leach from the polymeric component, impacting the pharmaceutical product quality or process performance. Thus, extractable & leachable testing has become crucial for single-use systems.

Application Insights

The orally inhaled and nasal drug products segment was the largest in 2022 andaccounted for the largest revenue share of 42.16%. Orally inhaled and nasal drug products include nasal sprays, metered dose inhalers, dry powder inhalers, nebulizers, and inhalers. These products are widely used for systemic delivery of various therapeutics. These products represent the highest-risk drug products concerning the possible introduction of contaminants via container closure contact. Moreover, these products are used indiseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Therefore, extractable and leachable testing is vital for orally inhaled and nasal drug products.

Thus, increasing the demand for extractable and leachable testing services over the forecast period. The parenteral drug products segment is projected to witness the fastest CAGR of 17.33% over the forecast period. The segment growth is driven by the rising adoption of parenteral preparations across end-users and the increasing burden of chronic conditions requiring parenteral products. Moreover, parenteral products usually have high concentrations of additives like solubilizing agents, plasticizers, etc., which may leach over time, thus, growing the demand for extractable and leachable testing services market.

Regional Insights

The U.S. held the largest market share of 57.19% in 2022. The large share of the country can be attributed to the presence of advanced healthcare infrastructure, the flourishing pharmaceutical & biotechnology sector, and the presence of a large number of market participants. Some of the key players offering E&L testing services are Eurofins Scientific; Sartorius AG; Pacific Biolabs; and Element Material Technology. Stringent government regulations for the safety and quality of healthcare products are encouraging these companies to develop precise analytical solutions for healthcare products. For instance, Eurofins Scientific developed its Good Manufacturing Products (GMP)-compliant protocols for direct E&L testing.

Europe is expected to witness a significant CAGR of 14.87% from 2023 to 2032. The growth can be attributed to the presence of developed economies like the UK, Germany, Spain, France, and Italy. These countries have an established infrastructure, which is anticipated to significantly boost the demand for healthcare products in the region. Moreover, the market growth can be attributed to a growing biotechnology & pharmaceutical industry and rising investments by the key players. Furthermore, supportive government regulations and the presence of numerous testing service providers are augmenting market growth; thus, boosting the demand for extractable and leachable testing services in this region.

Key Companies & Market Share Insights

Market leaders are involved in extensive R&D for manufacturing cost-efficient and technologically advanced testing products. Several strategies, such as mergers & acquisitions, undertaken by these organizations to expand their market presence are anticipated to create significant growth opportunities over the forecast period. For instance, in March 2023, Nelson Labs Europe collaborated with Nemera, a drug delivery device solutions provider, to offer integrated services to customers. This partnership was anticipated to benefit biotech & pharmaceutical customers by supplying drug compatibility lab testing, analytical chemistry, and expert advice.Some of the key players in the U.S. & Europe extractable and leachable testing services market include:

• Eurofins Scientific
• Intertek Group plc
• SGS Société Générale de Surveillance SA
• WuXi AppTec
• Merck KGaA
• West Pharmaceutical Services, Inc
• Wickham Micro Ltd. (Medical Engineering Technologies Ltd.)
• Pacific Biolabs
• Boston Analytical
• Sotera Health (Nelson Laboratories, LLC)

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. & Europe Extractable And Leachable Testing Services market.

By Product 

• Container Closure Systems
• Single-use Systems
• Drug Delivery Systems
• Others

By Application 

• Parenteral Drug Products
• Orally Inhaled and Nasal Drug Products (OINDP)
• Ophthalmic

By Region

• U.S.
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway